Observing the uncertainty of the Amlodipine-Candesartan Incremental Cost-Effectiveness ratio using Deterministic Sensitivity Analysis (DSA)

Najmiatul Fitria; Yolanda Zazna Syaputri; Lailaturrahmi Lailaturrahmi; Hansen Nasif

doi:10.30595/jhepr.v2i2.118

Authors

Najmiatul Fitria Faculty of Pharmacy, Universitas Andalas, Padang
Yolanda Zazna Syaputri Faculty of Pharmacy, Universitas Andalas
Lailaturrahmi Lailaturrahmi Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
Hansen Nasif Faculty of Pharmacy, Universitas Andalas

DOI:

https://doi.org/10.30595/jhepr.v2i2.118

Keywords:

Amlodipine, Candesartan, Cost-effectiveness, ICER, DSA

Abstract

Background: Hypertension treatment is carried out for a long time and can cause quite large costs. This study delves into the economic evaluation of Amlodipine-Candesartan combination therapy, a prominent treatment for hypertension. While the clinical benefits of this regimen are well-documented, its cost-effectiveness remains a critical consideration for healthcare systems. Employing Deterministic Sensitivity Analysis (DSA). This study aimed to discern the uncertainty surrounding the Incremental Cost-Effectiveness Ratio (ICER) associated with Amlodipine-Candesartan through comprehensive examination, next to refine economic assessments and offer insights for healthcare policymakers and practitioners. Method: This retrospective descriptive study at Andalas University Hospital in 2021 analyzed hypertension outpatient data. Of 284 patients, 73 were included. Among them, 28.77% received Amlodipine monotherapy, while 71.23% received Amlodipine-Candesartan combination therapy. Results: The ICER for systolic blood pressure was Rp. 74,738.10 per mmHg decrease, and for diastolic blood pressure, it was Rp. 205,918.24 per mmHg decrease. Both of them are in the northeast quadrant. Next, DSA will be carried out by creating a tornado diagram by providing a change range of 20% (min-max) for the input variables in ICER. Conclusion: The use of amlodipine-candesartan requires a higher cost, but the resulting effect is also better. Our findings contribute to the broader discourse on combination therapies and inform resource allocation strategies for hypertension management. This research attempts to enhance the precision of economic evaluations, ultimately facilitating more informed and efficient healthcare decision-making processes.

Keywords: Amlodipine, Candesartan, Cost-effectiveness, ICER, DSA.

References

Nuraini, B. Risk Factors of Hypertension. J Major. 4, 10–19 (2015).

Violán, C. et al. Burden of multimorbidity, socioeconomic status and use of health services across stages of life in urban areas: A cross-sectional study. BMC Public Health 14, (2014).

Duplaga, M. A cross-sectional study assessing determinants of the attitude to the introduction of eHealth services among patients suffering from chronic conditions. BMC Med. Inform. Decis. Mak. 15, 33 (2015).

Cicero, A. F. G., Fogacci, F. & Borghi, C. Cost-effectiveness analysis of different hypertension management strategies. Intern. Emerg. Med. 15, 181–182 (2020).

Renee, J. A. Pharmacoeconomics From Theory to Practice. (CRC Press, 2021).

Dilokthornsakul, P., Thomas, D., Brown, L. & Chaiyakunapruk, N. Interpreting Pharmacoeconomic Findings. in Clinical Pharmacy Education, Practice and Research 277 (Elsevier, 2018).

Fitria, N., Wulansari, S. & Sari, Y. O. Potential Interactions Analysis of Antihypertensive Drugs Used in Geriatric. Int. J. Appl. Pharm. 15, 29–33 (2023).

Sohn, I. S. et al. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. Clin. Ther. 39, 1628–1638 (2017).

Limwattananon, S. Sensitivity analysis for handling uncertainty in an economic evaluation. J. Med. Assoc. Thai. 97 Suppl 5, S59-64 (2014).

Liu, X.-Q. et al. Cost-effectiveness analyses of sacubitril-valsartan for heart failure. Heart Fail. Rev. 26, 1119–1130 (2021).

Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Heal. 25, 3–9 (2022).

The Equator Network. Enhancing the QUAlity and Transparency Of health Research. (2023).

Fitria, N., Fitri Anggraini, L. & Oktavia Sari, Y. Cost-Effectiveness Analysis of the Combination of Metformin-Insulin Glargine and Metformin-Glimepiride in Type 2 Diabetes Mellitus Patients in Rupit Hospital. Journal of Health Economic and Policy Research JHEPR vol. 1 (2023).

Ersa, C. B. et al. Kualitas hidup Orang dengan HIV / AIDS di Klinik VCT RSUD Raden Mattaher Jambi. 5, 66–79 (2023).

Suhery, D., Sari, Y. O. & Fitria, N. Analisa Hubungan Biaya Total dan Lama Rawatan Penggunaan Risperidon dan Quetiapin pada Pasien Skizofrenia Paranoid di RS Jiwa Prof HB Saanin Padang kepada Fasilitas Kesehatan Tingkat penggunaan Risperidon kombinasi lebih kelompok penggunaan Haloperidol. 15, (2023).

Pusat Pembiayaan dan Jaminan Kesehatan, Kementrian Kesehatan RI & Kemenkes RI. Buku Panduan Penilaian Teknologi Kesehatan Efektivitas Klinis dan Evaluasi Ekonomi. p 1-44 (2017).

Abdullah, A. Amlodipin Telmisartan Pada Pasien Penyakit Rsup Dr Wahidin Sudirohusodo Pharmacoeconomy Analysis of Amlodipin , Combination of Amlodipin-Valsartan and Amlodipin-Telmisartan for Diabetik Kidney Disease Patient in Lontara 1 Rsup Dr Wahidin Program Pascasarj. (2020).

Park, C., Wang, G., Durthaler, J. M. & Fang, J. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review. Am. J. Prev. Med. 53, S131–S142 (2017).

Ravangard, R., Jalali, F. S., Hajahmadi, M. & Jafari, A. Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran. Health Econ. Rev. 13, 44 (2023).